Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | SVP, Chief Accounting Officer | September 15, 2026 | September 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ultragenyx Pharmaceutical Inc.
Report date September 15, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 67,863 |
Reported balance
After 2026-09-15 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-15 · Sale · Disposed 1,283 · Balance 67,863 F1: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2018 Filed May 22, 2018 15:44 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 156 | $64.79 | $10,107.24 |
DisclosureSEC source: 0001209191-18-032208 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · VP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,711 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F3 · balance_after: Includes 393 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2018. Read SEC document |
| April 19, 2018 Filed Apr 19, 2018 20:52 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 799 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-025602 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · VP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,474 F1 · shares: Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on April 19, 2018 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:25 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 7,975 | $0.00 Strike: $48.43 | $0.00 |
DisclosureSEC source: 0001209191-18-016455 · doc4.xml · derivative · entry 3 Huizenga Theodore Alan · CIK 0001603347 · VP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,975 Underlying: Common Stock · 7,975 shares Expires 2028-03-01 F5 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:25 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 110 | $48.43 | $5,327.30 |
DisclosureSEC source: 0001209191-18-016455 · doc4.xml · nonDerivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · VP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,675 F4 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:25 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 1,313 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-016455 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · VP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,785 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F3 · balance_after: Includes 106 shares acquired under the Company's 2014 Employee Stock Purchase Plan on October 31, 2017. Read SEC document |
| May 26, 2017 Filed May 26, 2017 22:34 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 480 | $57.46 | $27,580.80 |
DisclosureSEC source: 0001209191-17-036024 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · VP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,366 F1 · shares: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units. Read SEC document |
| May 21, 2017 Filed May 22, 2017 22:56 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 166 | $57.47 | $9,540.02 |
DisclosureSEC source: 0001209191-17-034480 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · VP, Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,846 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units. F2 · balance_after: Includes 303 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 28, 2017. Read SEC document |
| March 09, 2017 Filed Mar 10, 2017 22:04 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 2,500 | $86.34 | $215,845.00 |
DisclosureSEC source: 0001209191-17-019902 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,709 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $86.12 to $86.71 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 21:06 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantEmployee Stock Option (Right to Buy) · Derivative | 6,450 | $0.00 Strike: $88.80 | $0.00 |
DisclosureSEC source: 0001209191-17-016513 · doc4.xml · derivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,450 Underlying: Common Stock · 6,450 shares Expires 2027-03-01 F3 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 21:06 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 1,075 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-016513 · doc4.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,209 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 21:11 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionStock Options (Right to buy) · Derivative | 2,000 | $0.00 Strike: $21.00 | $0.00 |
DisclosureSEC source: 0001562180-16-003581 · primarydocument.xml · derivative · entry 3 Huizenga Theodore Alan · CIK 0001603347 · Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,403 Underlying: Common Stock · 2,000 shares Expires 2024-01-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 1/4 of the shares underlying the option vested on January 27, 2015, with 1/48th of the underlying shares vesting monthly thereafter, provided the Reporting Person has not terminated services with the Issuer. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 21:11 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 2,000 | $79.73 | $159,460.00 |
DisclosureSEC source: 0001562180-16-003581 · primarydocument.xml · nonDerivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,134 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.70 to $79.82 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F1 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions. F2 · balance_after: Due to a clerical error, the Forms 4 filed by the Reporting Person on each of June 19, 2015, December 18, 2015, January 19, 2016, February 17, 2016, May 24, 2016, and May 27, 2016 listed incorrect amounts in Column 5. The Form 4 filed on June 19, 2015 has been amended to reflect the correct share ownership following the reported transaction of 4,300 shares rather than 2,500 shares. The Form 4 filed on December 18, 2015 should have reflected 4,300 shares rather than 2,500 shares; the Form 4 filed on January 19, 2016 should have reflected 5,300 shares rather than 3,500 shares; the Form 4 filed on February 17, 2016 should have reflected 6,300 shares rather than 4,500 shares; the Form 4 filed May 24, 2016 should have reflected 6,134 shares rather than 4,334 shares; and the Form 4 filed on May 27, 2016 should have reflected 11,134 shares rather than 9,334 shares. Read SEC document |
| November 16, 2016 Filed Nov 18, 2016 21:11 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionCommon Stock | 2,000 | $21.00 | $42,000.00 |
DisclosureSEC source: 0001562180-16-003581 · primarydocument.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,134 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting Person, which are subject to certain vesting conditions. F2 · balance_after: Due to a clerical error, the Forms 4 filed by the Reporting Person on each of June 19, 2015, December 18, 2015, January 19, 2016, February 17, 2016, May 24, 2016, and May 27, 2016 listed incorrect amounts in Column 5. The Form 4 filed on June 19, 2015 has been amended to reflect the correct share ownership following the reported transaction of 4,300 shares rather than 2,500 shares. The Form 4 filed on December 18, 2015 should have reflected 4,300 shares rather than 2,500 shares; the Form 4 filed on January 19, 2016 should have reflected 5,300 shares rather than 3,500 shares; the Form 4 filed on February 17, 2016 should have reflected 6,300 shares rather than 4,500 shares; the Form 4 filed May 24, 2016 should have reflected 6,134 shares rather than 4,334 shares; and the Form 4 filed on May 27, 2016 should have reflected 11,134 shares rather than 9,334 shares. Read SEC document |
| June 17, 2015 Filed Nov 18, 2016 21:03 UTC Amendment | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 1,500 | $94.80 | $142,200.00 |
DisclosureSEC source: 0001562180-16-003577 · primarydocument.xml · nonDerivative · entry 2 Huizenga Theodore Alan · CIK 0001603347 · Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,300 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $94.76 to $94.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. F1 · balance_after: Due to a clerical error, the number of shares beneficially owned following the reported transaction mistakenly excluded 1,800 shares owned by the Reporting Person. These 1,800 shares were also omitted from five Forms 4 filed by the Reporting Person after this Form 4 was filed. Read SEC document |
| June 17, 2015 Filed Nov 18, 2016 21:03 UTC Amendment | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Exercise / conversionCommon Stock | 1,500 | $21.00 | $31,500.00 |
DisclosureSEC source: 0001562180-16-003577 · primarydocument.xml · nonDerivative · entry 1 Huizenga Theodore Alan · CIK 0001603347 · Controller and PAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,800 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Due to a clerical error, the number of shares beneficially owned following the reported transaction mistakenly excluded 1,800 shares owned by the Reporting Person. These 1,800 shares were also omitted from five Forms 4 filed by the Reporting Person after this Form 4 was filed. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.